

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

(Use as many sheets as necessary)

Sheet	1	of	7
-------	---	----	---

**Complete if Known**

Application Number	10/539,049
Filing Date	16 December 2003
First Named Inventor	ABBOTT, Frank Slade
Art Unit	
Examiner Name	
Attorney Docket Number	U008 0645

## U. S. PATENT DOCUMENTS


[illegible]

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 801.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

**If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.**



PTO/SB/08B (07-05)  
Approved for use through 07/31/2006. OMB 0651-0031  
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE  
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)		<b>Complete if Known</b>			
		Application Number	10/539,049		
		Filing Date	16 December 2003		
		First Named Inventor	ABBOTT, Frank Slade		
		Art Unit			
		Examiner Name			
Sheet	2	of	7	Attorney Docket Number	U008 0645


NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
/ML/		Dreifuss, F. E., Santili, N., Langer, D. H., Sweeny, K. P., Moline, K. A., Menander, K. B., Valproic acid hepatic fatalities: a retrospective*, Neurology, 37, 379-385 (1987).	
		Kesterson, J.W. et al., The hepatotoxicity of valproic acid and its metabolites in rats. I. Toxicologic, biochemical and histopathologic studies, Hep., 4, 1143-1152 (1984).	
		Kingsley, E.; Gray, P.; Tolman, K. G.; Tweedale, R. The toxicity of metabolites of sodium valproate in cultured hepatocytes, J. Clin. Pharmacol., 23, 178-185 (1983).	
		Kassahun, K., Farrell, K., Abbott, F.S., Identification and characterization of the glutathione and N-acetylcysteine*, Drug Metab. Dispos., 19, 525-535 (1991).	
		Genton, P. et al., Valproic Acid, Adverse Effects, in Antiepileptic Drugs, 5th edition, Rene H Levy et al. eds., Lippincott Williams and Wilkins, NY, 2002, p 837-851.	
		Abbott, F. S., Anari, M. R., "Chemistry and biotransformation" in Valproate, Milestones in Drug Therapy, W. Loscher, ed., Birhauser Verlag, Basel, 1999, p. 47-75.	
		Radatz, M.; Nau, H. "Toxicity" in Valproate, Milestones in Drug Therapy, W. Loscher, ed., Birhauser Verlag, Basel, 1999, p. 91-128.	
		Tabatabaei, A. R. et al., A rapid in vitro assay for evaluation of metabolism-dependent cytotoxicity of antiepileptic drugs*, Fundam Appl Toxicol. 37, 181-189 (1997).	
		Winn, L. M., Wells, P. G., Maternal administration of superoxide dismutase and catalase in phenytoin teratogenicity, Free Radic. Biol. Med., 26, 266-274 (1999).	
/ML/		Tang, W. et al., Fluorinated analogues as mechanistic probes in valproic acid (VPA) hepatotoxicity: Hepatic microvesicular*, Chem. Res. Toxicol., 8, 671-682 (1995).	

Examiner Signature	/Marialouisa Lao/	Date Considered	04/12/2007
--------------------	-------------------	-----------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



PTO/SB/08B (07-05)  
Approved for use through 07/31/2008, OMB 0651-0031  
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 3

of

7

### Complete if Known

Application Number	10/539,049
Filing Date	16 December 2003
First Named Inventor	ABBOTT, Frank Slade
Art Unit	
Examiner Name	
Attorney Docket Number	U008 0645

### NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
/ML/		Tang, W. et al., Characterization of thiol conjugated metabolites of 2-propyl-4-pentenoic acid (4-ene-VPA), a toxic metabolite of valp* J. Mass Spectrom., 31, 926-936 (1996).	
		Tang, W., Palaty, J., Abbott, F. S., Time course of $\alpha$ -fluorinated valproic acid in mouse brain and serum and its effect on sym.* J. Phar. Exp. Therap, 282, 1163-1172 (1997).	
		Palaty, J., Abbott, F. S. Structure-activity relationships of unsaturated analogues of valproic acid, J. Med. Chem., 38, 3398-3406 (1995).	
		Düsing, R. H., Single dose tolerance and pharmacokinetics of 2-n-propyl-(2E)-pentenoate $\cdot$ 2E-valproate) in healthy male volunteers, Pharm. Week., 14, 152-158 (1992).	
		Elmazar, M. M. A., Hauck, R.-S., Nau, H., Anticonvulsant and neurotoxic activities of twelve analogues of valproic acid, J. Pharm. Sci., 82, 1255-1258 (1993).	
		Hauck, R. S., Nau, H., The enantiomers of the valproic acid analog 2-n-propyl-4-pentynoic acid (4-yn-VPA): asymmetry synthesis and highly stereo*, Pharm. Res., 9, 855 (1992).	
		Parisi, M. F., Gattuso, G., Notti, A., and Raymo, F. M., J. Org. Chem., 1995, 60, 5174-5179.	
		Litchfield, J. T., Wilcoxon, F. J. Phar. Exp. Ther., 1949, 96, 99-113.	
		Tong, V., Chang, T. K. H., Chen, J., Abbott, F. S., The effect of valproic acid on hepatic and plasma levels of 15-F2t-Isopro*, Free Radic. Biol. Med., 34, 1435-1446 (2003).	
/ML/		Sokol, R. J. et al., Role of oxidant stress in the permeability transition induced in rat hepatic mitochondria by hydrophobic bile acids, Pediatric Res., 49, 519-531 (2001).	

Examiner Signature	/Marialouisa Lao/	Date Considered	04/12/2007
--------------------	-------------------	-----------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.88. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



PTO/SB/08B (07-05)  
Approved for use through 07/31/2006. OMB 0651-0031  
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE  
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.


<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)		<b>Complete if Known</b>	
		Application Number	10/539,049
		Filing Date	16 December 2003
		First Named Inventor	ABBOTT, Frank Slade
		Art Unit	
		Examiner Name	
Sheet 4	of 7	Attorney Docket Number	U008 0645

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
/ML/		Qu, B. et al., Mechanism of clofibrate hepatotoxicity: Mitochondrial damage and oxidative stress in hepatocytes, Free Radic. Biol. Med., 31, 659-669 (2001).	
		Tang, W., Abbott, F. S., A comparative investigation of 2-propyl-4-pentenoic acid (4-ene-VPA) and its -fluorinated analogue in: phase*, Drug Metab. Disp., 25, 219-227 (1997).	
		Tsunoda, T., Suzuki, M., Noyori, R. A., A facile procedure for acetalization under aprotic conditions, Tetrahedron Lett., 21, 1357-1358 (1980).	
		Ohshima T. Et al., Asymmetric Heck Reaction - Carbanion Capture Process. Catalytic Asymmetric Total Synthesis of (-)-9(12)-Cap*, J. Am. Chem. Soc., 118, 7108-7116 (1996).	
		Aubert, C. et al., Alkylation du trifluoroacetylacetate d'ethyle methode generale d'accès aux trifluoromethylcetonés. Zieme partie: Alkyla*, J. Fluor. Chem., 44, 377-394 (1989).	
		Montes de Lopez-Cepero, I., Santiago, A., Larson, G. L., A Synthesis of 2,2-ethylenedioxy-5-ketones, Synth. Commun., 16, 705-711 (1986).	
		Kurihara, M., Hakamata, W., Convenient preparation of cyclic acetals, using diols, TMS-source, and a catalytic amount of TMSOTf, J. Org. Chem., 68, 3413-34515 (2003).	
		Middleton, W. J., New fluorinating reagents. Dialkylaminosulfur fluorides, J. Org. Chem., 40, 574-578 (1975).	
		Middleton, W. J., Bingham, E. M., -, -Difluoroarylacetic acids: Preparation from (diethylamino)sulfur trifluoride and -oxoarylacates, J. Org. Chem., 45, 2883-2887 (1980).	
/ML/		Lal, G. S. et al., Bis(2-methoxyethyl)aminosulfur trifluoride: A new broad-spectrum deoxofluorinating agent with enhanced thermal stab.*, J. Org. Chem. 64, 7048-7054 (1999).	

Examiner Signature	/Marialouisa Lao/	Date Considered	04/12/2007
--------------------	-------------------	-----------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.  
1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.  
This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



PTO/SB/08B (07-05)  
Approved for use through 07/31/2006. OMB 0651-0031  
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)		<b>Complete if Known</b>			
		Application Number	10/539,049		
		Filing Date	16 December 2003		
		First Named Inventor	ABBOTT, Frank Slade		
		Art Unit			
		Examiner Name			
Sheet	5	of	7	Attorney Docket Number	U008 0645


NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
/ML/		Lal, G. S. et al., Bis(2-methoxyethyl)amino sulfur trifluoride: A new broad-spectrum deoxofluorinating agent with enhanced thermal stability, Chem. Commun., 215-216 (1998).	
		Singh, R. P., Majumder, U., Shreeve, J. M., Nucleophilic Di- and Tetrafluorination of dicarbonyl compounds, J. Org. Chem., 66, 6263-6267 (2001).	
		Tsuji, J., Synthetic applications of the palladium-catalyzed oxidation of olefins to ketones, Synthesis, 369-384 (1983).	
		Tsuji, J., Mizatani, K., Shimzu, I., Yamamoto, K., Synthesis of 2,15-hexadecanedione, a precursor of muscone, from butadiene, Chem. Lett., 773-774 (1976).	
		Tsuji, J. et al., Convenient general synthetic method for 1,4- and 1,5-diketones by palladium catalyzed oxidation of*, Tetrahedron Lett., 34, 2975-2976 (1976).	
		Brun, E. M., Gil. S., Mestres, R., Parra, M., Regioselective alkylation of lithium dienediolates of *, -unsaturated carboxylic acids, Synthesis, 1160-1165 (2000).	
		Brun, E. M., Gil. S., Mestres, R., Parra, M., New conditions for the generation of dianions of carboxylic acids, Tethedron Lett., 39, 5443-5446 (1998).	
		Yoshida, Y. et al., Practical and efficient methods for sulfonylation of alcohols using Ts(Ms)Cl/Et <sub>3</sub> N and*Tetrahedron, 55, 2183-2192 (1999).	
		Wakabayashi, T., Mori, K., Kobayashi, S., Total synthesis and structural elucidation of Khafrefungin, J. Am. Chem. Soc., 123, 1372-1375 (2001).	
/ML/		Lee, R. D., Kassahun, K., Abbott, F. S., Stereoselective synthesis of the diunsaturated metabolites of valproic acid, J. Pharm. Sci., 78, 667-671 (1989).	

Examiner Signature	/Marialouisa Lao/	Date Considered	04/12/2007
--------------------	-------------------	-----------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



PTO/SB/08B (07-05)  
 Approved for use through 07/31/2006. OMB 0651-0031  
 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE  
 Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO		<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)		Application Number	10/539,049
		Filing Date	16 December 2003
		First Named Inventor	ABBOTT, Frank Slade
		Art Unit	
		Examiner Name	
Sheet 6	of 7	Attorney Docket Number	U008 0645

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
/ML/		Maryanoff, B.E.; Reitz, A.B. Chem. Rev. 1989, 89, 863-927 and references therein.	
		(a) DiBiase, S.A.; Lipisko, B.A.; Haag, A.; Wolak, R.A.; Gokel, G.W. J. Org. Chem. 1979, 44, 4640-4649;	
		(b) Wu, K.M.; Midland, M.M.; Okamura, W.H. J. Org. Chem. 1990, 55, 4355, 4381-4392;	
		(c) Clive, D.L.J.; Farina, V.; Beaulieu, P.L. J. Org. Chem. 1982, 47, 2572-2582;	
		(d) Ono, N.; Miyake, H.; Tanikaga, R.; Kaji, A. J. Org. Chem. 1982, 47, 5017-5019.	
		Takacs, J.M.; Jaber, M.R.; Clement, F.; Walters, C. J. Org. Chem. 1998, 63, 6757- 6760.	
		Bonadies, F.; Cardilli, A.; Lattanzi, A.; Orelli, L.R.; Scettri, A. Tetrahedron Letters 1994, 35, 3383-3386.	
		Bennani, Y.L.; Boehm, M.F. J. Org. Chem. 1995, 60, 1195-1200.	
		Motoyoshiya, J. Trends in Organic Chemistry, 1998, 7, 63-73 and references therein.	
/ML/		Pihko, P.M.; Salo, T.M. Tetrahedron Letters, 2003, 44, 4361-4364 and references therein.	

Examiner Signature	/Marialouisa Lao/	Date Considered	04/12/2007
--------------------	-------------------	-----------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.  
<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.  
 This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



PTO/SB/08B (07-05)  
Approved for use through 07/31/2006. OMB 0651-0031  
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)		<b>Complete if Known</b>	
		Application Number	10/539,049
		Filing Date	16 December 2003
		First Named Inventor	ABBOTT, Frank Slade
		Art Unit	
		Examiner Name	
Sheet 7	of 7	Attorney Docket Number	U008 0645

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
/ML/		INTERNATIONAL SEARCHING AUTHORITY, International Search Report for PCT/CA03/01960, 2 August 2004, References cited below	
/ML/		DREIDING, Andre S. et al., ".alpha. - and .gamma. - Additions in the Reformatskii reaction with methyl gamma-bromocrotonate", Jr. of American Chem. Soc., 75:3717-23 (1953).	
/ML/		TAKEUCHI, Yoshio et al., "The first general and efficient method for synthesis of tertiary alkyl fluorides", Jr of Organic chem, 58(13), 3483-5 (1993).	
/ML/		MYERS, Andrew G. et al., "Synthesis of tertiary alkyl fluoride centers by asymmetric C-C(F) bond formation" Tetrahedron Letters, 38(40), 7037-7040 (1997).	
/ML/		ZHU, Gui-Dong et al., "Intramolecular Diels-Alder reaction of 8-trifluoromethyl-1,3,8-nonatrienes: an access to angular" Bull. Des Soc. Chim. Belges, 103(5-6), 263-71 (1994).	

Examiner Signature	/Marialouisa Lao/	Date Considered	04/12/2007
--------------------	-------------------	-----------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.88. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.